Kobayashi Pharmaceutical (4967) Fundamentals 2026 — P/E 132.0x, Revenue Analysis | SniperIQ
Kobayashi Pharmaceutical (4967) is a JP-listed Consumer Defensive company in Household & Personal Products with a market capitalization of ¥405.1B, trading at ¥5450.00 on the JPX. This SniperIQ fundamentals page covers Kobayashi Pharmaceutical's valuation (P/E 132.0x, P/B 1.9x), profitability (net margin 1.8%), revenue (¥165.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Kobayashi Pharmaceutical's market cap?
Kobayashi Pharmaceutical (4967) has a market capitalization of approximately ¥405.1B, trading at ¥5450.00 on the JPX. Market cap moves with the live share price.
What is Kobayashi Pharmaceutical's P/E ratio?
Kobayashi Pharmaceutical's trailing twelve-month P/E ratio is 132.0x, with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Kobayashi Pharmaceutical?
Kobayashi Pharmaceutical runs a net profit margin of 1.8%, a gross margin of 51.0%, and an operating margin of 8.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Kobayashi Pharmaceutical generate?
Kobayashi Pharmaceutical reported revenue of ¥165.7B for fiscal year 2025, with net income of ¥3.7B and earnings per share (EPS) of 49.18. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Kobayashi Pharmaceutical pay a dividend?
Kobayashi Pharmaceutical offers a trailing dividend yield of about 1.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Kobayashi Pharmaceutical financially healthy?
Kobayashi Pharmaceutical carries a debt-to-equity ratio of 0.00x and a current ratio of 3.04x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Kobayashi Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kobayashi Pharmaceutical (4967) the key facts are: market cap ¥405.1B, P/E 132.0x, revenue ¥165.7B, 52-week range 5030-6140. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Kobayashi Pharmaceutical's full fundamentals live
Get Kobayashi Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.